Background and Aims Malformations of cortical development (MCDs) are increasingly recognized as important causes of epilepsy. The aims of this study was to evaluate the presentation and severity of epilepsy in the different types of MCDs in children.

Methods Neuroimaging data of patients with epilepsy and MCDs in MRI were evaluated for a period from 2000–2011. The case records were taken from the medical file.

Results We are reporting 13 cases (9 boys and 3 girls) of MCDs. The mean age at onset of seizure was 20 months (2 months–8 years). Psychomotor retardation were present in 5 patients. Craniofacial dysmorphism was noted in 4 cases and microcephaly in 6 cases. Hypotonia and subsequently limb hypertonia were noted in 5 cases. Partial seizure was seen in 5 patients followed by infantile spasms in 3 cases. EEG demonstrated focal epileptiform discharges in 4 cases, and hypsarythmia in 2 cases. Cortical dysplasia was seen in 4 patients, polymicrogyria in 3 patients, lissencephaly in 4 patients and schizencephaly in one patient. Heterotopias were seen in 3 patients in combination with other malformations. Genetic analysis for Miller-Diker syndrome showed mutations of the LIS1 gene on chromosome 17 in one case. Only 5 Patients had their seizures controlled by antiepileptic drugs (2 patients with cortical dysplasia and 3 with polymicrogyria).

Conclusion MR imaging allows the detection and classification of MCDs. An adequate classification of these malformations should help to provide to the family an appropriate counseling both in terms of genetics and outcome.

ACUTE DISSEMINATED ENCEPHALOMYELITIS IN CHILDREN (EIGHT CASES REPORTS)

H Ajmi, S Hassayoun, S Mabrouk, N Zouari, S Elkhnissi, J Chemli, S Abroug, K Tili, A Harbi. Pediatric Department, Sahhlou Hospital, Sousse, Tunisia

Background Acute disseminated encephalomyelitis (ADEM) is an immune-mediated inflammatory disorder of the central nervous system, characterized by a widespread demyelination that predominantly involves the white matter of the brain and spinal cord.

We aimed to assess the clinical presentations, neuroimaging, treatment, and outcome of eight children with ADEM.

Methods An 11-years retrospective chart review of children with the diagnosis of ADEM was conducted during the period between 2000 and 2011. The diagnosis of ADEM was carried in front of clinical and radiological signs.

Results Eight cases of ADEM, aged between 9 months and 14 years, were identified. The clinical picture is characterized by multiple symptoms. Prominent findings are seizures in three cases, altered level of consciousness in seven cases and motor system dysfunction in five cases. Brain magnetic resonance imaging evaluations had been done in all patients and revealed demyelinated lesions in the cerebral cortex, subcortical white matter, in periventricular white matter, in deep gray matter and in brainstem in all patients. Spinal cord MRI was performed in one case and showed demyelinated lesions in cervical and dorsalate age. All patients were treated with high-dose intravenous methylprednisolone pulse therapy during six days, related by oral corticoetherapy. Five of them received also intravenous immunoglobulins. The evolution was favorable in all patients, only one had mild long-term optic neuropathy sequelae.

Conclusion Clinical features of ADEM are similar to those of infectious encephalitis. The neuroimaging test of choice to establish the diagnosis is MRI. In most patients, the prognosis is good after treatment.

BDNF AND OXIDATIVE STRESS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

W MVO Alves, W PRA Carvalho, W Junior, W Michalowski, W LE Daoud, W L Stertz, W Ferrari, W CS Gama, W Kapanski. Universidade Federal do Rio Grande do Sul and Hospital de Clinicas de Porto Alegre; Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Background Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, representing nearly one third of all pediatric cancers. Nowadays overall cure rates for children with ALL have reached 90% due to great improvements in diagnosis and treatment. Unfortunately, the increase in survival rates have been associated with an increase in treatment related toxicity. Survivors may experience late effects from treatment for this condition, such as learning disability and cognitive defects even with no cranial radiation. BDNF levels have been associated with cognitive deficits, among others conditions.

Objectives To evaluate the BDNF levels and oxidative stress in patients with acute lymphoblastic leukemia (ALL).

Design and methods We measured serum concentrations of brain derived neurotrophic factor (BDNF), serumthiobarbituric acid reactive substances (TBARS), serum protein carbonylation, serum IL-6 and IL-10 before and after 72 hours intrathecal methotrexate (MTX). This study was performed on 8 children with ALL during the treatment with BFM protocol and in 40 controls.

Results BDNF levels were lower in ALL patients than in controls (p<0.001). BDNF levels before and after intrathecal MTX had not showed significant alterations. Serum protein carbonylation was lower after complete remission.

Conclusion These findings suggested that there is oxidative stress and decreased levels of serum BDNF in patients with acute lymphoblastic leukemia. The treatment may have a protective role in relation to oxidative stress and possible cognitive deficits.
1504 BDNF and Oxidative Stress in Children with Acute Lymphoblastic Leukemia

MMO Alves, PRA Carvalho, J Marchesan, M Michalowski, LLE Daudt, L Stertz, P Ferrari, CS Gama and F Kapzinski

Arch Dis Child 2012 97: A426
doi: 10.1136/archdischild-2012-302724.1504

Updated information and services can be found at:
http://adc.bmj.com/content/97/Suppl_2/A426.2

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/